Search results
Results from the WOW.Com Content Network
The Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) is a source of epidemiologic information on the incidence and survival rates of cancer in the United States.
The Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute (NCI) was established in 1973 as a result of the National Cancer Act of 1971. The National Program of Cancer Registries (NPCR) was established by Congress through the Cancer Registries Amendment Act in 1992, and administered by the Centers for Disease ...
In 2021, NCI undertook a pilot project to oversample cancer survivors using three cancer registries from the Surveillance, Epidemiology, and End Results (SEER) Program (https://seer.cancer.gov) as a sampling frame of cancer survivors. The pilot project, called HINTS-SEER, was designed to provide a larger sample of cancer survivors for analyses.
The epidemiology of cancer is the study of the factors affecting cancer, as a way to infer possible trends and causes. The study of cancer epidemiology uses epidemiological methods to find the cause of cancer and to identify and develop improved treatments. This area of study must contend with problems of lead time bias and length time bias ...
The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services.
The Center for Surveillance, Epidemiology and Laboratory Services (CSELS) is a branch of the US Centers for Disease Control and Prevention (CDC) that provides scientific service, expertise, skills, and tools in support of national efforts to promote health; prevent disease, injury and disability; and prepare for emerging health threats. [1]
Survival rate is a part of survival analysis.It is the proportion of people in a study or treatment group still alive at a given period of time after diagnosis. It is a method of describing prognosis in certain disease conditions, and can be used for the assessment of standards of therapy.
Patients in response categories 4-9 should be considered as failing to respond to treatment (disease progression). Thus, an incorrect treatment schedule or drug administration does not result in exclusion from the analysis of the response rate. Precise definitions for categories 4-9 will be protocol specific.